Asia Fresh News

Asia Fresh Stories

Archive for July 24th, 2012

Bradesco’s Results 每 First Half of 2012

leave a comment »

SAO PAULO, July 23, 2012 /PRNewswire-Asia/ — The main figures obtained by Bradesco (BM&FBovespa: BBDC3; BBDC4), (NYSE: BBD) in the first half of 2012 are presented below:

1. Adjusted Net Income(1) in the first half of 2012 stood at R$5.712 billion (a 2.7% increase compared to the R$5.563 billion recorded in the same period last year), corresponding to earnings per share of R$2.97 in the last 12 months and Return on Average Shareholders’ Equity(2) of 20.6%.

2. Adjusted Net Income is composed of R$3.926 billion from financial activities, representing 68.7% of the total, and R$1.786 billion from insurance, pension plan and capitalization bond operations, which accounted for 31.3%.

3. On June 30, 2012, Bradesco’s market capitalization stood at R$104.869 billion(3).

4. Total Assets stood at R$830.520 billion in June 2012, a 20.5% increase over the same period in 2011. Return on Total Average Assets was 1.4%.

5. The Expanded Loan Portfolio(4) stood at R$364.963 billion in June 2012, up 14.1% on the same period in 2011. Operations with individuals totaled R$112.235 billion (up 9.1%), while operations with companies totaled R$252.728 billion (up 16.5%).

6. Assets under Management stood at R$1.131 trillion, up 21.0% on June 2011.

7. Shareholders’ Equity stood at R$63.920 billion in June 2012, up 21.0% on June 2011. Capital Adequacy Ratio stood at 17.0% in June 2012, 11.8% of which fell under Tier I Capital.

8. Interest on Shareholders’ Equity and Dividends were paid and recorded in provision to shareholders for income in the first half of 2012 in the amount of R$1,916 million, of which R$1,122 million was paid as monthly and interim dividends and R$794 million was recorded in provision.

9. Financial Margin stood at R$21.729 billion, up 15.4% in comparison with the first half of 2011.

10. The Delinquency Ratio over 90 days stood at 4.2% on June 30, 2012 (3.7% on June 30, 2011).

11. The Efficiency Ratio(5) improved by 0.3 p.p. (from 42.7% in June 2011 to 42.4% in June 2012) and the “adjusted-to-risk” ratio stood at 53.1% (52.2% in June 2011).

12. Insurance Written Premiums, Pension Plan Contributions and Capitalization Bond Income totaled R$20.988 billion the first half of 2012, up 20.1% over the same period in 2011. Technical Reserves stood at R$111.789 billion, up 19.0% on June 2011.

13. Investments in infrastructure, information technology and telecommunications amounted to R$1.986 billion in the first half of 2012, a 14.1% increase on the previous year.

14. Taxes and contributions, including social security, paid or recorded in provision, amounted to R$11.483 billion, of which R$4.945 billion referred to taxes withheld and collected from third parties and R$6.538 billion from Bradesco Organization activities, equivalent to 114.5% of Adjusted Net Income (1).

15. Bradesco has an extensive customer service network in Brazil, comprising 7,893 service points (4,650 branches and 3,243 Service Branches – PAs). Customers can also use 1,476 PAEs 每 ATMs (Automatic Teller Machines) in companies, 40,476 Bradesco Expresso service points, 35,226 Bradesco Dia & Noite ATMs and 12,258 Banco24Horas ATMs.

16. Payroll, plus charges and benefits, totaled R$5.002 billion. Social benefits provided to the 104,531 employees of the Bradesco Organization and their dependents amounted to R$1.202 billion, while investments in training and development programs totaled R$62.599 million.

17. Major Awards and Recognitions in the period:

— Bradesco was recognized as the “Best Brazilian Bank” and “Latin America’s
Best Bank” in the 2012 edition of the Euromoney Awards for Excellence,
which is annually granted by British magazine Euromoney, renowned as one
of the world’s most important in the financial institution segment;
Bradesco is one of the world’s most solid banks. It ranked 13th among 20
global institutions, and is the only truly Brazilian bank in the ranking
(Bloomberg News);
— Bradesco is the private company with the most valuable brand in Brazil.
In general ranking (including government companies), it placed second
among 480 brands in 32 categories, and placed first among Latin American
companies (BrandAnalytics / Millward Brown 每 IstoE magazine);
— Bradesco Organization stood out in the Best and Largest 2012 edition: it
ranked first among the “200 Largest Groups” and “50 Largest Banks that
Operate in Brazil,” and it is also the private financial institution with
highest number of demand deposits and rural loans, checking account
holders and active credit cards. In the insurance segment, Grupo Bradesco
Seguros e Previdencia occupied three the top six positions in the
insurance segment ranking in Brazil through Bradesco Saude (first),
Bradesco Vida e Previdencia and Bradesco Auto/RE (Exame magazine);
— The Organization was granted the “Best Company to Launch a Career Award,”
in the “Young Talent Retention” category (Voce S/A magazine in
partnership with FIA 每 Fundacao Instituto de Administracao);
— Bradesco won the “2012 Consumidor Moderno” Award for Excellence in
Customer Service, in the “Premium Bank” and “Credit Card” categories
(Consumidor Moderno magazine 每 Grupo Padrao); and
— The Investor Relations area was awarded the “Best Investor Relations of
the Financial Sector,” according to IR Magazine Awards Brazil 2012.

18. With regards to sustainability, Bradesco divides its actions into three pillars: (i) Sustainable Finances, focused on banking inclusion, social and environmental variables for loan approvals and offering social and environmental products; (ii) Responsible Management, focused on valuing professionals, improving the workplace and adopting eco-efficient practices; and (iii) Social and Environmental Investments, focused on education, the environment, culture and sports. In this area, we point out Fundacao Bradesco, which has a 55-year history of extensive social and educational work, with 40 schools in Brazil. In 2012, a projected budget of R$385.473 million will benefit 111,170 students in its schools, in Basic Education (from Kindergarten to High School and Vocational Training – High School Level), Education for Youth and Adults; and Preliminary and Continuing Qualification focused on the creation of jobs and generation of income. The nearly 50 thousand students in Basic Education are guaranteed free, quality education, uniforms, school supplies, meals and medical and dental assistance. Fundacao Bradesco also aided another 300,150 students through its distance learning programs, found at its e-learning portal “Virtual School.” These students completed at least one of the many courses offered by the Virtual School. Furthermore, another 83,323 people will benefit from projects and actions in partnerships with Digital Inclusion Centers (CIDs), the Educa+Acao Program and Technology courses (Educar e Aprender 每 Teach and Learn).

The Financial Statements can be found on Bradesco’s Investor Relations website at

(1) According to non-recurring events described on page 8 of this Report on Economic and Financial Analysis; (2) Excludes mark-to-market effect of available-for-sale securities recorded under Shareholders’ Equity; (3) R$114.304 billion considering the closing price of preferred shares (most traded share); (4) Includes sureties and guarantees, letters of credit, advances of credit card receivables, co-obligation in loan assignment (receivables-backed investment funds and mortgage-backed receivables), co-obligation in rural loan assignment, and operations bearing credit risk 每 commercial portfolio, which includes debentures and promissory notes; and (5) In the last 12 months.

Mrs. Ivani Benazzi de Andrade
Phone: +55-11-2178-6218

or Mr. Carlos Tsuyoshi Yamashita
Phone: +55-11-2178-6204

SOURCE﹛Banco Bradesco S.A.

Written by asiafreshnews

July 24, 2012 at 5:28 pm

Posted in Uncategorized

Berg Pharma launches clinical trial on BPM 31543 for prevention of chemotherapy-induced alopecia (CIA)

leave a comment »

NEW YORK, July 23, 2012 /PRNewswire-Asia/ — Berg Pharma, a Boston-based pharmaceutical company focused on discovery and development of new treatments in cancer and metabolic diseases, announced the initiation of a clinical trial entitled “Phase I Dose-Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of a Topical Compound 31543 in Adult Patients Receiving Chemotherapy for the Treatment of Breast Cancer.” The trial will be conducted at Memorial Sloan-Kettering Cancer Center in New York City.


Chemotherapy-induced alopecia (“CIA”) has been cited as the most disturbing anticipated side effect by the majority of women preparing for chemotherapy, with nearly 10% being at risk of avoiding treatment due to anticipated hair loss. There is currently no treatment available to prevent CIA and causes the patient significant psychological stress and self-awareness of being in a cancer state. Joaquin J. Jimenez, MD, Associate Professor at the University of Miami Miller School of Medicine, Department of Dermatology & Cutaneous Surgery and an international leader in hair research said, “We have reached a pivotal point in which research meets clinical innovation. There is no doubt that the partnership of Berg Pharma and Memorial Sloan- Kettering will bring us closer to finding a solution for chemotherapy-induced alopecia.”

Mario Lacouture, MD, Associate Attending Dermatologist at Memorial Sloan-Kettering Cancer Center and Principal Investigator of the trial, said, “Hair loss can be one of the most devastating side effects of chemotherapy treatment so we are very excited to evaluate this new treatment in the hopes of potentially eliminating or greatly diminishing something that both men and women consider to be a major stigma of many chemotherapeutic treatments.”

This Phase I trial has primary objectives of safety and pharmacokinetics and secondary objectives designed to evaluate the ability of the topical drug to prevent or diminish hair loss (alopecia) associated with chemotherapy treatments. Moderate to severe hair loss and hair thinning is a common side effect of many chemotherapeutic agents used to treat cancers. Linda Vahdat, MD, Professor of Medicine, Head, Solid Tumor Service, and Director of the Breast Cancer Research Program at Weill Cornell Medical School said, “The breast cancer research group at Cornell is actively involved in strategies to prevent chemotherapy induced alopecia so we are very excited to see this trial initiated and look forward to its results.”

Niven R. Narain, Co-founder, President & CTO of Berg Pharma said, “This is clearly an unmet need in cancer therapy and partnering with a world-class investigator and institution to advance BPM 31543 into clinical development is very exciting. Berg is committed to treating not only cancer but also the harsh side effects seen with some chemotherapy regimens.”

Patient recruitment for the Phase I study had begun at the Evelyn H. Lauder Breast Center at 66th Street and Second Avenue in New York City. Detailed information on patient eligibility can be found at identifier NCT01588522.

About Berg Pharma

Berg Pharma is a Boston based pharmaceutical company and parent company to Berg Biosystems and Berg Diagnostics. Our research focus seeks to understand how alterations in metabolism relate to disease onset. We have uncovered key insight into metabolic control factors and namely into underlying elements in the Warburg Hypothesis. The Company has a deep pipeline of early-stage technologies in CNS diseases and metabolic diseases that complement its late-stage clinical trial activity in cancer and prevention of chemotoxicity. Armed with use of the discovery platform that translates biological output into viable therapeutics and a robust biomarker library, Berg Pharma is poised to realize its pursuit of a healthier tomorrow.

SOURCE﹛Berg Pharma

Written by asiafreshnews

July 24, 2012 at 4:45 pm

Posted in Uncategorized